Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
13.89
-0.43 (-3.00%)
At close: Oct 29, 2025, 4:00 PM EDT
13.00
-0.89 (-6.40%)
After-hours: Oct 29, 2025, 7:53 PM EDT
Amylyx Pharmaceuticals Employees
Amylyx Pharmaceuticals had 123 employees as of December 31, 2024. The number of employees decreased by 261 or -67.97% compared to the previous year.
Employees
123
Change (1Y)
-261
Growth (1Y)
-67.97%
Revenue / Employee
n/a
Profits / Employee
-$1,525,203
Market Cap
1.48B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 123 | -261 | -67.97% |
| Dec 31, 2023 | 384 | 122 | 46.56% |
| Dec 31, 2022 | 262 | 57 | 27.80% |
| Dec 31, 2021 | 205 | 171 | 502.94% |
| Dec 31, 2020 | 34 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AMLX News
- 2 days ago - Halper Sadeh LLC Encourages Amylyx Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
- 13 days ago - AMYLYX INVESTIGATION: Bragar Eagel & Squire, P.C. Urges Amylyx Investors to Contact the Firm Regarding Ongoing Investigation into Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders - GlobeNewsWire
- 7 weeks ago - Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock - Business Wire
- 7 weeks ago - Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock - Business Wire
- 7 weeks ago - Amylyx Pharmaceuticals, Inc. (AMLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Amylyx Pharmaceuticals, Inc. (AMLX) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 2 months ago - Amylyx to stop development of rare brain disorder drug after trial failure - Reuters
- 2 months ago - Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP) - Business Wire